HQ Specialty Pharma Seeks to Correct Patent and Block Fresenius Kabi Competitor After Delaware Jury Ruling

HQ Specialty Pharma Corp. has announced plans to address deficiencies in its patent for an injectable calcium supplement. This move follows a recent decision by a federal jury in Delaware, which found the patent partially invalid. According to HQ Specialty, once the corrections are made, they intend to pursue a court order aimed at preventing Fresenius Kabi USA LLC from marketing its competing product, which HQ Specialty claims is infringing on their patent. For more details, the original report can be found on Law360.